Literature DB >> 23264652

Regulation of TLR2-mediated tolerance and cross-tolerance through IRAK4 modulation by miR-132 and miR-212.

Md A Nahid1, Bing Yao, Paul R Dominguez-Gutierrez, Lakshmyya Kesavalu, Minoru Satoh, Edward K L Chan.   

Abstract

Innate immune response is the first defense against pathogens via recognition by various conserved pattern recognition receptors, such as TLRs, to initiate a rapid and strong cytokine alarm. TLR signaling-mediated cytokine production must be properly regulated to prevent pathological conditions deriving from overproduction of cytokines. In this study, the role of specific microRNAs in TLR-signaling pathway was investigated to reveal the cross-interaction and -regulation in the MyD88 pathway. In peptidoglycan (PGN)/TLR2-stimulated THP-1 monocytes, PBMCs, and primary macrophages showed rapid and dramatic miR-132 and miR-212 (miR-132/-212) upregulation. This newly identified response appeared earlier in time than the characteristic miR-146a response in LPS-TLR4 stimulation. The rapid induction of miR-132/-212 was transcription factor CREB dependent, and the sustained expression of miR-132/-212 was responsible for inducing tolerance to subsequent PGN challenge. Cross-tolerance was observed by TLR5 ligand flagellin and heat-killed or live bacteria resulting from miR-132/-212 upregulation. Mechanistically, IRAK4 was identified and validated as a target of miR-132/-212 by luciferase reporter assay and seed-sequence mutagenesis of the reporter. Transfection of miR-132 or miR-212 alone mimicked PGN tolerance in monocytes, whereas transfected specific miRNA inhibitors tampered the tolerance effect. During bacterial infection, PGN-mediated TLR2 signaling induces miR-132/-212 to downregulate IRAK4, an early component in the MyD88-dependent pathway, whereas LPS/TLR4-induced miR-146a downregulates downstream components of the same MyD88-dependent pathway. The identification of miR-132/-212 and miR-146a together to prevent damaging consequences from the overproduction of proinflammatory cytokines by targeting a common signaling pathway is significant and will provide insights into future design and development of therapeutics.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23264652      PMCID: PMC3552145          DOI: 10.4049/jimmunol.1103060

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  56 in total

1.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

Review 2.  Peptidoglycan recognition proteins (PGRPs).

Authors:  Roman Dziarski
Journal:  Mol Immunol       Date:  2004-02       Impact factor: 4.407

3.  Involvement of IRAK-M in peptidoglycan-induced tolerance in macrophages.

Authors:  Kuniko Nakayama; Shu Okugawa; Shintaro Yanagimoto; Takatoshi Kitazawa; Kunihisa Tsukada; Miki Kawada; Satoshi Kimura; Koichi Hirai; Yohtaroh Takagaki; Yasuo Ota
Journal:  J Biol Chem       Date:  2003-12-04       Impact factor: 5.157

4.  IRAK-M is a negative regulator of Toll-like receptor signaling.

Authors:  Koichi Kobayashi; Lorraine D Hernandez; Jorge E Galán; Charles A Janeway; Ruslan Medzhitov; Richard A Flavell
Journal:  Cell       Date:  2002-07-26       Impact factor: 41.582

5.  Inhibition of lipopolysaccharide-induced signal transduction in endotoxin-tolerized mouse macrophages: dysregulation of cytokine, chemokine, and toll-like receptor 2 and 4 gene expression.

Authors:  A E Medvedev; K M Kopydlowski; S N Vogel
Journal:  J Immunol       Date:  2000-06-01       Impact factor: 5.422

6.  Characterization of interleukin-1 receptor-associated kinase in normal and endotoxin-tolerant cells.

Authors:  L Li; S Cousart; J Hu; C E McCall
Journal:  J Biol Chem       Date:  2000-07-28       Impact factor: 5.157

7.  Severe impairment of interleukin-1 and Toll-like receptor signalling in mice lacking IRAK-4.

Authors:  Nobutaka Suzuki; Shinobu Suzuki; Gordon S Duncan; Douglas G Millar; Teiji Wada; Christine Mirtsos; Hidetoshi Takada; Andrew Wakeham; Annick Itie; Shyun Li; Josef M Penninger; Holger Wesche; Pamela S Ohashi; Tak W Mak; Wen-Chen Yeh
Journal:  Nature       Date:  2002-03-31       Impact factor: 49.962

8.  Regulation of the miR-212/132 locus by MSK1 and CREB in response to neurotrophins.

Authors:  Judit Remenyi; Christopher J Hunter; Christian Cole; Hideaki Ando; Soren Impey; Claire E Monk; Kirsty J Martin; Geoffrey J Barton; Gyorgy Hutvagner; J Simon C Arthur
Journal:  Biochem J       Date:  2010-05-13       Impact factor: 3.857

9.  Lipopolysaccharide- and lipoteichoic acid-induced tolerance and cross-tolerance: distinct alterations in IL-1 receptor-associated kinase.

Authors:  Randy Jacinto; Thomas Hartung; Charles McCall; Liwu Li
Journal:  J Immunol       Date:  2002-06-15       Impact factor: 5.422

10.  Nod1 detects a unique muropeptide from gram-negative bacterial peptidoglycan.

Authors:  Stephen E Girardin; Ivo G Boneca; Leticia A M Carneiro; Aude Antignac; Muguette Jéhanno; Jérôme Viala; Karsten Tedin; Muhamed-Kheir Taha; Agnes Labigne; Ulrich Zähringer; Anthony J Coyle; Peter S DiStefano; John Bertin; Philippe J Sansonetti; Dana J Philpott
Journal:  Science       Date:  2003-06-06       Impact factor: 47.728

View more
  63 in total

1.  MicroRNA-132, miR-146a, and miR-155 as potential biomarkers of methotrexate response in patients with rheumatoid arthritis.

Authors:  Ankita Singh; Pradeepta Sekhar Patro; Amita Aggarwal
Journal:  Clin Rheumatol       Date:  2018-12-03       Impact factor: 2.980

2.  Positive correlation of STAT1 and miR-146a with anemia in patients with systemic lupus erythematosus.

Authors:  Paul R Dominguez-Gutierrez; Angela Ceribelli; Minoru Satoh; Eric S Sobel; Westley H Reeves; Edward K L Chan
Journal:  J Clin Immunol       Date:  2013-12-01       Impact factor: 8.317

3.  Identification of novel MicroRNA signatures linked to experimental autoimmune myasthenia gravis pathogenesis: down-regulated miR-145 promotes pathogenetic Th17 cell response.

Authors:  Jiao Wang; Shuangshuang Zheng; Ning Xin; Changxin Dou; Linlin Fu; Xiuying Zhang; Jing Chen; Yanyan Zhang; Deqin Geng; Chenghua Xiao; Guiyun Cui; Xia Shen; Yang Lu; Jinhua Wang; Ruiguo Dong; Yuehua Qiao; Yong Zhang
Journal:  J Neuroimmune Pharmacol       Date:  2013-09-17       Impact factor: 4.147

4.  Regulation of activation-associated microRNA accumulation rates during monocyte-to-macrophage differentiation.

Authors:  Renee L Eigsti; Bayan Sudan; Mary E Wilson; Joel W Graff
Journal:  J Biol Chem       Date:  2014-08-22       Impact factor: 5.157

Review 5.  MicroRNAs as regulatory elements in immune system logic.

Authors:  Arnav Mehta; David Baltimore
Journal:  Nat Rev Immunol       Date:  2016-04-28       Impact factor: 53.106

6.  The inducible microRNA-203 in fish represses the inflammatory responses to Gram-negative bacteria by targeting IL-1 receptor-associated kinase 4.

Authors:  Tianjun Xu; Qing Chu; Junxia Cui; Xueyan Zhao
Journal:  J Biol Chem       Date:  2017-12-14       Impact factor: 5.157

7.  MicroRNAs Modulate Pathogenesis Resulting from Chlamydial Infection in Mice.

Authors:  Laxmi Yeruva; Dakota L Pouncey; Michael R Eledge; Sudeepa Bhattacharya; Chunqiao Luo; Erin W Weatherford; David M Ojcius; Roger G Rank
Journal:  Infect Immun       Date:  2016-12-29       Impact factor: 3.441

8.  Interleukin 1β-Responsive MicroRNA-146a Is Critical for the Cytokine-Induced Tolerance and Cross-Tolerance to Toll-Like Receptor Ligands.

Authors:  Md A Nahid; Minoru Satoh; Edward K L Chan
Journal:  J Innate Immun       Date:  2015-04-18       Impact factor: 7.349

Review 9.  Bridging Autism Spectrum Disorders and Schizophrenia through inflammation and biomarkers - pre-clinical and clinical investigations.

Authors:  Joana Prata; Susana G Santos; Maria Inês Almeida; Rui Coelho; Mário A Barbosa
Journal:  J Neuroinflammation       Date:  2017-09-04       Impact factor: 8.322

Review 10.  Role of innate immunity in the development of hepatocellular carcinoma.

Authors:  Rajagopal N Aravalli
Journal:  World J Gastroenterol       Date:  2013-11-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.